Yulu F. Wang
Bonn, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
PTPN6/SHP-1 in autoimmune disease: immune tolerance, regulatory mechanisms, and therapeutic targeting.
Journal: Frontiers in immunology
Published: March 26, 2026
Hiding in plain sight: Pathogenic insights from nonlesional skin in gliptin-associated bullous pemphigoid.
Journal: The Journal of investigative dermatology
Published: February 25, 2026
The Secretome of Bullous Pemphigoid IgG-Treated Keratinocytes Induces a Pro-Inflammatory Eosinophil Response.
Journal: Experimental dermatology
Published: February 02, 2026
CD24 in Melanoma: Biomarker, Innate Immune Checkpoint and Emerging Therapeutic Target.
Journal: Experimental dermatology
Published: January 31, 2026
Review of Low-Dose Naltrexone for Hailey-Hailey Disease Suggests Lack of Benefit in Dose Escalation.
Review of Low-Dose Naltrexone for Hailey-Hailey Disease Suggests Lack of Benefit in Dose Escalation.
Journal: International journal of dermatology
Published: January 16, 2026
Racial differences in comorbidities and mortality in US patients with bullous pemphigoid: A propensity matched cohort study.
Journal: Journal of the American Academy of Dermatology
Published: December 09, 2025
Association of immune checkpoint inhibitor-induced bullous pemphigoid with underlying cancer type: A lack of association with cancer tissue COL17A1 mutations and dysregulation.
Journal: JID innovations : skin science from molecules to population health
Published: October 01, 2025
WHOLE TRANSCRIPTION ANALYSIS IDENTIFIED THE REGULATION OF HYPOXIA-INDUCIBLE FACTORS IN MONOCYTES WITH IMMUNE SUPPRESSION: IMPLICATIONS FOR CLINICAL OUTCOMES.
Journal: Shock (Augusta, Ga.)
Published: October 15, 2024
FOXN3-AS1: A Candidate Prognostic Marker and Epigenetic Target with Immunotherapeutic Implications in Acute Myeloid Leukemia.
Journal: Current medicinal chemistry
Published: February 17, 2024
Last Updated: 09/26/2026